Calidi Biotherapeutics Inc (CLDI) vs. Its Peers: A Comparison

Additionally, the 36-month beta value for CLDI is 0.70. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for CLDI is 25.65M and currently, short sellers hold a 0.18% ratio of that float. The average trading volume of CLDI on May 24, 2024 was 959.46K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

CLDI) stock’s latest price update

Calidi Biotherapeutics Inc (AMEX: CLDI)’s stock price has gone rise by 5.39 in comparison to its previous close of 0.23, however, the company has experienced a -1.36% decrease in its stock price over the last five trading days. reported 2024-05-17 that ORLANDO, FL / ACCESSWIRE / May 17, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics Inc. (NYSE American:CLDI) and Unusual Machines Inc. (NYSE American:UMAC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 18, at 7 p.m. Eastern Time (ET).

CLDI’s Market Performance

Calidi Biotherapeutics Inc (CLDI) has seen a -1.36% fall in stock performance for the week, with a 51.17% gain in the past month and a -76.83% plunge in the past quarter. The volatility ratio for the week is 9.79%, and the volatility levels for the past 30 days are at 17.17% for CLDI. The simple moving average for the last 20 days is 10.51% for CLDI’s stock, with a simple moving average of -90.07% for the last 200 days.

Analysts’ Opinion of CLDI

Many brokerage firms have already submitted their reports for CLDI stocks, with H.C. Wainwright repeating the rating for CLDI by listing it as a “Buy.” The predicted price for CLDI in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on November 22, 2023 of the previous year 2023.

Robert W. Baird, on the other hand, stated in their research note that they expect to see CLDI reach a price target of $9. The rating they have provided for CLDI stocks is “Outperform” according to the report published on October 09th, 2023.

CLDI Trading at -35.90% from the 50-Day Moving Average

After a stumble in the market that brought CLDI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.27% of loss for the given period.

Volatility was left at 17.17%, however, over the last 30 days, the volatility rate increased by 9.79%, as shares surge +49.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.11% lower at present.

During the last 5 trading sessions, CLDI fell by -1.36%, which changed the moving average for the period of 200-days by -97.73% in comparison to the 20-day moving average, which settled at $0.2199. In addition, Calidi Biotherapeutics Inc saw -84.19% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for CLDI

Equity return is now at value -212.68, with -85.99 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 0.13.


In conclusion, Calidi Biotherapeutics Inc (CLDI) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts